249
this post was submitted on 20 May 2024
249 points (92.8% liked)
Technology
59374 readers
3463 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
The dude is fine and actually pretty lucky. Its sad that it stopped working but its not like he died or something.
You have no idea what the long term effects of the rejection are going to be, and neither does the corporation doing this to human beings after killing a bunch of monkeys and still failing.
What's the alternative? We either don't create this technology at all or we do and accept the fact that it's going to involve a lot of trial and error. You don't just skip all that and jump to the final product. There's only so much you can test on animals which exactly isn't the most ethical thing to begin with anyway. At some point you're going to need to stick it in a human brain.
The first heart transplant recepient died after 18 days. Should we have not done that either?
That's just untrue. There are a lot of options between "give up" and "proceed irresponsibly". After all the animals they've scrapped why are the human subjects having the EXACT SAME PROBLEMS that were identified in the animals. This is Musk's typical "fail fast" strategy to advance research faster, but in the medical field the failures damage real humans.
Completely irresponsible!
The FDA regulatory failure with neuralink is as bad as the FAA's failure with Boeing.